Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Pancreatic Cancer|Breast Cancer|Gastric Cancer|Non Small Cell Lung Cancer|Cervical Cancer|Endocervical Cancer|Squamous Cell Carcinoma of Head and Neck|Bladder Urothelial Cancer|Colorectal Cancer|Esophageal Cancer|Ovarian Cancer|Renal Cell Carcinoma|Prostate Cancer|Melanoma|Mesothelioma|Cholangiocarcinoma
Interventions: DRUG: NGM438|DRUG: Pembrolizumab
Sponsor: NGM Biopharmaceuticals, Inc
Collaborators: Merck Sharp & Dohme LLC